NCT05379803View on ClinicalTrials.gov

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Furmonertinib

furmonertinib 160 mg orally QD

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER